Economic evaluation of sublingual immunotherapy vs. symptomatic treatment in allergic asthma. (Q51137105)

30 March 2018

title

Economic evaluation of sublingual immunotherapy vs. symptomatic treatment in allergic asthma. (English)

1 reference

30 March 2018

0 references

1 reference

6

1 reference

30 March 2018

Giuseppe Di Cara

object named as

Giuseppe Di Cara

4

0 references

Cristoforo Incorvaia

3

object named as

Cristoforo Incorvaia

1 reference

30 March 2018

8

Franco Frati

1 reference

30 March 2018

author name string

Renato Ariano

1

1 reference

30 March 2018

Patrizia Berto

2

1 reference

30 March 2018

Rachele Boccardo

5

1 reference

30 March 2018

Paola Puccinelli

7

1 reference

30 March 2018

publication date

1 September 2009

1 reference

30 March 2018

Annals of Allergy, Asthma & Immunology

published in

1 reference

30 March 2018

volume

103

1 reference

30 March 2018

issue

3

1 reference

30 March 2018

page(s)

254-259

1 reference

30 March 2018

Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960190-1

7 January 2021

Intergenerational 20 year trends in the prevalence of asthma and hay fever in adults: the Midspan family study surveys of parents and offspring

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960190-1

7 January 2021

Direct costs of allergic rhinitis in the United States: estimates from the 1996 Medical Expenditure Panel Survey

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960190-1

7 January 2021

The economic burden of allergic rhinitis: a critical evaluation of the literature.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960190-1

7 January 2021

Cost of illness of atopic asthma and seasonal allergic rhinitis in Germany: 1-yr retrospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960190-1

7 January 2021

The burden of atopy and asthma in children

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960190-1

7 January 2021

The health economics of asthma and rhinitis. I. Assessing the economic impact

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960190-1

7 January 2021

A comprehensive study of the direct and indirect costs of adult asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960190-1

7 January 2021

Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960190-1

7 January 2021

Ragweed immunotherapy in adult asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960190-1

7 January 2021

Utilization and cost of immunotherapy for allergic asthma and rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960190-1

7 January 2021

Economic evaluation of specific immunotherapy versus symptomatic treatment of allergic rhinitis in Germany.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960190-1

7 January 2021

Health-economic analyses of subcutaneous specific immunotherapy for grass pollen and mite allergy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960190-1

7 January 2021

Economic evaluation of sublingual immunotherapy vs symptomatic treatment in adults with pollen-induced respiratory allergy: the Sublingual Immunotherapy Pollen Allergy Italy (SPAI) study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960190-1

7 January 2021

Comparison of costs of sublingual immunotherapy and drug treatment in grass-pollen induced allergy: results from the SIMAP database study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960190-1

7 January 2021

Visual analog scales can assess the severity of rhinitis graded according to ARIA guidelines.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960190-1

7 January 2021

Economic studies of immunotherapy: a review

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960190-1

7 January 2021

Cost-effectiveness of grass allergen tablet (GRAZAX) for the prevention of seasonal grass pollen induced rhinoconjunctivitis - a Northern European perspective.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960190-1

7 January 2021

Cost-effectiveness of GRAZAX for prevention of grass pollen induced rhinoconjunctivitis in Southern Europe

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960190-1

7 January 2021

The safety of sublingual-swallow immunotherapy: an analysis of published studies

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960190-1

7 January 2021

10.1016/S1081-1206(10)60190-1

Identifiers

DOI

1 reference

30 March 2018

1 reference

30 March 2018